LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "fgfr2 fusion" as a keyword



HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma

Sign Up to like & get
recommendations! Published in 2019 at "Hepatology"

DOI: 10.1002/hep.30127

Abstract: About 15% of intrahepatic cholangiocarcinomas (ICCs) express constitutively active fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs) generated by chromosomal translocations. FFs have been nominated as oncogenic drivers because administration of FGFR tyrosine kinase… read more here.

Keywords: hsp90; fusion proteins; fgfr2 fusion; bgj398 ... See more keywords

Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

Sign Up to like & get
recommendations! Published in 2023 at "Journal for ImmunoTherapy of Cancer"

DOI: 10.1136/jitc-2022-006303

Abstract: Background Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is associated with dismal prognosis. In a previous case report, adoptive transfer… read more here.

Keywords: recognition; fusion; fgfr2 fusion; tumor ... See more keywords

FGFR2-Rearrangement in Intrahepatic and Extrahepatic Cholangiocarcinoma and Prognostic Analysis

Sign Up to like & get
recommendations! Published in 2025 at "International Journal of General Medicine"

DOI: 10.2147/ijgm.s526759

Abstract: Aim To investigate the clinicopathological features and prognostic factors of intrahepatic and extrahepatic cholangiocarcinoma. Methods Clinicopathological and follow-up data of 328 cholangiocarcinoma patients treated at Shanxi Cancer Hospital from November 7, 2016, to August 11,… read more here.

Keywords: fgfr2 fusion; cholangiocarcinoma; extrahepatic cholangiocarcinoma; expression ... See more keywords

Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor–Pretreated FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma: Case Report

Sign Up to like & get
recommendations! Published in 2024 at "OncoTargets and Therapy"

DOI: 10.2147/ott.s434449

Abstract: Abstract Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced FGFR2 fusion–positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATP-competitive FGFR inhibitors in a subset of… read more here.

Keywords: fgfr; fgfr2 fusion; cholangiocarcinoma; inhibitor ... See more keywords

Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion

Sign Up to like & get
recommendations! Published in 2024 at "AntiCancer Research"

DOI: 10.21873/anticanres.17046

Abstract: Background/Aim: Cholangiocarcinoma (CCA) is an aggressive tumor with limited treatment options especially in 2nd line or later treatments. Targeting fibroblast growth factor receptor (FGFR) 2 has recently emerged as a promising treatment option for patients… read more here.

Keywords: orally available; fgfr2 fusion; available fgfr1; fgfr1 inhibitor ... See more keywords